Analysts offer the following ratings for Bristol-Myers Squibb: BMY Within the last quarter:
strong | somewhat bullish | indifference | somewhat bearish | bearish | |
---|---|---|---|---|---|
comprehensive evaluation | 0 | 3 | 2 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M ago | 0 | 1 | 0 | 0 | 0 |
2M ago | 0 | 0 | 1 | 0 | 0 |
3M ago | 0 | 1 | 1 | 0 | 0 |
These five analysts set an average price target of $85.8 for Bristol-Myers Squibb, which is currently at $72.75, suggesting an upside.
Below is a summary of how these five analysts rated Bristol-Myers Squibb over the past three months. The higher the number of bullish ratings, the more analysts are positive about the stock, and the higher the number of bearish ratings, the more analysts are negative about the stock.
This current average price is a 5.93% increase from the previous average price target of $81.00.
Get the latest Bristol-Myers Squibb analyst ratings.
Analysts are experts in banking and financial systems and typically report within specific stocks or defined sectors. These people study company financial statements, participate in conference calls and conferences, and speak with relevant insiders to determine what is known as an analyst’s stock valuation. Typically, an analyst evaluates each stock once per quarter.
Some analysts also provide forecasts for metrics such as growth forecasts, earnings, and earnings to provide further guidance on stocks. Investors using analyst ratings should be aware that this professional advice is human and subject to error.
This article was generated by Benzinga’s automated content engine and reviewed by editors.